What is the current valuation of the Phytopathological Disease Diagnostics Market?

The market valuation reached 2.208 USD Billion in 2024. Read More

What is the projected market size for the Phytopathological Disease Diagnostics Market by 2035?

The market is expected to grow to 4.487 USD Billion by 2035. Read More

What is the expected CAGR for the Phytopathological Disease Diagnostics Market during the forecast period?

The market is projected to experience a CAGR of 6.66% from 2025 to 2035. Read More

Which pathogen type segment is anticipated to have the highest growth in the market?

The Fungi segment is expected to grow from 0.8 USD Billion in 2024 to 1.6 USD Billion by 2035. Read More

How does the Fruits and Vegetables crop type segment perform in the market?

The Fruits and Vegetables segment is projected to increase from 0.6 USD Billion in 2024 to 1.2 USD Billion by 2035. Read More

What diagnostic method is likely to dominate the Phytopathological Disease Diagnostics Market?

Molecular Diagnostics is expected to lead, growing from 0.8 USD Billion in 2024 to 1.6 USD Billion by 2035. Read More

What sample type segment shows promising growth in the market?

The Plant Tissue sample type is anticipated to expand from 0.8 USD Billion in 2024 to 1.6 USD Billion by 2035. Read More

What is the purpose of diagnostics that is projected to see the most growth?

Early Detection and Diagnosis is expected to grow from 0.883 USD Billion in 2024 to 1.785 USD Billion by 2035. Read More

Who are the key players in the Phytopathological Disease Diagnostics Market?

Key players include Agdia Inc, Neogen Corporation, and Syngenta AG, among others. Read More

What role do companies like BASF SE and DuPont de Nemours Inc play in the market?

Companies like BASF SE and DuPont de Nemours Inc are significant contributors to the market's growth and innovation. Read More

Phytopathological Disease Diagnostics Market

ID: MRFR/MED/26118-HCR

100 Pages

Rahul Gotadki

Last Updated: April 06, 2026

Phytopathological Disease Diagnostics Market Research Report By Pathogen Type (Fungi, Bacteria, Viruses, Phytoplasmas, Nematodes), By Crop Type (Cereals and Grains, Fruits and Vegetables, Oilseeds and Pulses, Fiber Crops, Specialty Crops), By Diagnostic Method (Traditional Microscopy, Molecular Diagnostics, Biochemical Assays, Immunological Assays, Remote Sensing), By Sample Type (Plant Tissue, Soil, Water, Air), By Purpose of Diagnostics (Early Detection and Diagnosis, Disease Monitoring, Risk Assessment, Research and Development) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Phytopathological Disease Diagnostics Market Infographic

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Pathogen Type (USD Billion)
  1. 4.1.1 Fungi
  2. 4.1.2 Bacteria
  3. 4.1.3 Viruses
  4. 4.1.4 Phytoplasmas
  5. 4.1.5 Nematodes
2. 4.2 Healthcare, BY Crop Type (USD Billion)
  1. 4.2.1 Cereals and Grains
  2. 4.2.2 Fruits and Vegetables
  3. 4.2.3 Oilseeds and Pulses
  4. 4.2.4 Fiber Crops
  5. 4.2.5 Specialty Crops
3. 4.3 Healthcare, BY Diagnostic Method (USD Billion)
  1. 4.3.1 Traditional Microscopy
  2. 4.3.2 Molecular Diagnostics
  3. 4.3.3 Biochemical Assays
  4. 4.3.4 Immunological Assays
  5. 4.3.5 Remote Sensing
4. 4.4 Healthcare, BY Sample Type (USD Billion)
  1. 4.4.1 Plant Tissue
  2. 4.4.2 Soil
  3. 4.4.3 Water
  4. 4.4.4 Air
5. 4.5 Healthcare, BY Purpose of Diagnostics (USD Billion)
  1. 4.5.1 Early Detection and Diagnosis
  2. 4.5.2 Disease Monitoring
  3. 4.5.3 Risk Assessment
  4. 4.5.4 Research and Development
6. 4.6 Healthcare, BY Region (USD Billion)
  1. 4.6.1 North America
    1. 4.6.1.1 US
    2. 4.6.1.2 Canada
  2. 4.6.2 Europe
    1. 4.6.2.1 Germany
    2. 4.6.2.2 UK
    3. 4.6.2.3 France
    4. 4.6.2.4 Russia
    5. 4.6.2.5 Italy
    6. 4.6.2.6 Spain
    7. 4.6.2.7 Rest of Europe
  3. 4.6.3 APAC
    1. 4.6.3.1 China
    2. 4.6.3.2 India
    3. 4.6.3.3 Japan
    4. 4.6.3.4 South Korea
    5. 4.6.3.5 Malaysia
    6. 4.6.3.6 Thailand
    7. 4.6.3.7 Indonesia
    8. 4.6.3.8 Rest of APAC
  4. 4.6.4 South America
    1. 4.6.4.1 Brazil
    2. 4.6.4.2 Mexico
    3. 4.6.4.3 Argentina
    4. 4.6.4.4 Rest of South America
  5. 4.6.5 MEA
    1. 4.6.5.1 GCC Countries
    2. 4.6.5.2 South Africa
    3. 4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Agdia Inc (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Neogen Corporation (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Romer Labs (AT)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bio-Rad Laboratories (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Eurofins Scientific (LU)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Syngenta AG (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 BASF SE (DE)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 DuPont de Nemours Inc (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Marrone Bio Innovations Inc (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY PATHOGEN TYPE
4. 6.4 US MARKET ANALYSIS BY CROP TYPE
5. 6.5 US MARKET ANALYSIS BY DIAGNOSTIC METHOD
6. 6.6 US MARKET ANALYSIS BY SAMPLE TYPE
7. 6.7 US MARKET ANALYSIS BY PURPOSE OF DIAGNOSTICS
8. 6.8 CANADA MARKET ANALYSIS BY PATHOGEN TYPE
9. 6.9 CANADA MARKET ANALYSIS BY CROP TYPE
10. 6.10 CANADA MARKET ANALYSIS BY DIAGNOSTIC METHOD
11. 6.11 CANADA MARKET ANALYSIS BY SAMPLE TYPE
12. 6.12 CANADA MARKET ANALYSIS BY PURPOSE OF DIAGNOSTICS
13. 6.13 EUROPE MARKET ANALYSIS
14. 6.14 GERMANY MARKET ANALYSIS BY PATHOGEN TYPE
15. 6.15 GERMANY MARKET ANALYSIS BY CROP TYPE
16. 6.16 GERMANY MARKET ANALYSIS BY DIAGNOSTIC METHOD
17. 6.17 GERMANY MARKET ANALYSIS BY SAMPLE TYPE
18. 6.18 GERMANY MARKET ANALYSIS BY PURPOSE OF DIAGNOSTICS
19. 6.19 UK MARKET ANALYSIS BY PATHOGEN TYPE
20. 6.20 UK MARKET ANALYSIS BY CROP TYPE
21. 6.21 UK MARKET ANALYSIS BY DIAGNOSTIC METHOD
22. 6.22 UK MARKET ANALYSIS BY SAMPLE TYPE
23. 6.23 UK MARKET ANALYSIS BY PURPOSE OF DIAGNOSTICS
24. 6.24 FRANCE MARKET ANALYSIS BY PATHOGEN TYPE
25. 6.25 FRANCE MARKET ANALYSIS BY CROP TYPE
26. 6.26 FRANCE MARKET ANALYSIS BY DIAGNOSTIC METHOD
27. 6.27 FRANCE MARKET ANALYSIS BY SAMPLE TYPE
28. 6.28 FRANCE MARKET ANALYSIS BY PURPOSE OF DIAGNOSTICS
29. 6.29 RUSSIA MARKET ANALYSIS BY PATHOGEN TYPE
30. 6.30 RUSSIA MARKET ANALYSIS BY CROP TYPE
31. 6.31 RUSSIA MARKET ANALYSIS BY DIAGNOSTIC METHOD
32. 6.32 RUSSIA MARKET ANALYSIS BY SAMPLE TYPE
33. 6.33 RUSSIA MARKET ANALYSIS BY PURPOSE OF DIAGNOSTICS
34. 6.34 ITALY MARKET ANALYSIS BY PATHOGEN TYPE
35. 6.35 ITALY MARKET ANALYSIS BY CROP TYPE
36. 6.36 ITALY MARKET ANALYSIS BY DIAGNOSTIC METHOD
37. 6.37 ITALY MARKET ANALYSIS BY SAMPLE TYPE
38. 6.38 ITALY MARKET ANALYSIS BY PURPOSE OF DIAGNOSTICS
39. 6.39 SPAIN MARKET ANALYSIS BY PATHOGEN TYPE
40. 6.40 SPAIN MARKET ANALYSIS BY CROP TYPE
41. 6.41 SPAIN MARKET ANALYSIS BY DIAGNOSTIC METHOD
42. 6.42 SPAIN MARKET ANALYSIS BY SAMPLE TYPE
43. 6.43 SPAIN MARKET ANALYSIS BY PURPOSE OF DIAGNOSTICS
44. 6.44 REST OF EUROPE MARKET ANALYSIS BY PATHOGEN TYPE
45. 6.45 REST OF EUROPE MARKET ANALYSIS BY CROP TYPE
46. 6.46 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSTIC METHOD
47. 6.47 REST OF EUROPE MARKET ANALYSIS BY SAMPLE TYPE
48. 6.48 REST OF EUROPE MARKET ANALYSIS BY PURPOSE OF DIAGNOSTICS
49. 6.49 APAC MARKET ANALYSIS
50. 6.50 CHINA MARKET ANALYSIS BY PATHOGEN TYPE
51. 6.51 CHINA MARKET ANALYSIS BY CROP TYPE
52. 6.52 CHINA MARKET ANALYSIS BY DIAGNOSTIC METHOD
53. 6.53 CHINA MARKET ANALYSIS BY SAMPLE TYPE
54. 6.54 CHINA MARKET ANALYSIS BY PURPOSE OF DIAGNOSTICS
55. 6.55 INDIA MARKET ANALYSIS BY PATHOGEN TYPE
56. 6.56 INDIA MARKET ANALYSIS BY CROP TYPE
57. 6.57 INDIA MARKET ANALYSIS BY DIAGNOSTIC METHOD
58. 6.58 INDIA MARKET ANALYSIS BY SAMPLE TYPE
59. 6.59 INDIA MARKET ANALYSIS BY PURPOSE OF DIAGNOSTICS
60. 6.60 JAPAN MARKET ANALYSIS BY PATHOGEN TYPE
61. 6.61 JAPAN MARKET ANALYSIS BY CROP TYPE
62. 6.62 JAPAN MARKET ANALYSIS BY DIAGNOSTIC METHOD
63. 6.63 JAPAN MARKET ANALYSIS BY SAMPLE TYPE
64. 6.64 JAPAN MARKET ANALYSIS BY PURPOSE OF DIAGNOSTICS
65. 6.65 SOUTH KOREA MARKET ANALYSIS BY PATHOGEN TYPE
66. 6.66 SOUTH KOREA MARKET ANALYSIS BY CROP TYPE
67. 6.67 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSTIC METHOD
68. 6.68 SOUTH KOREA MARKET ANALYSIS BY SAMPLE TYPE
69. 6.69 SOUTH KOREA MARKET ANALYSIS BY PURPOSE OF DIAGNOSTICS
70. 6.70 MALAYSIA MARKET ANALYSIS BY PATHOGEN TYPE
71. 6.71 MALAYSIA MARKET ANALYSIS BY CROP TYPE
72. 6.72 MALAYSIA MARKET ANALYSIS BY DIAGNOSTIC METHOD
73. 6.73 MALAYSIA MARKET ANALYSIS BY SAMPLE TYPE
74. 6.74 MALAYSIA MARKET ANALYSIS BY PURPOSE OF DIAGNOSTICS
75. 6.75 THAILAND MARKET ANALYSIS BY PATHOGEN TYPE
76. 6.76 THAILAND MARKET ANALYSIS BY CROP TYPE
77. 6.77 THAILAND MARKET ANALYSIS BY DIAGNOSTIC METHOD
78. 6.78 THAILAND MARKET ANALYSIS BY SAMPLE TYPE
79. 6.79 THAILAND MARKET ANALYSIS BY PURPOSE OF DIAGNOSTICS
80. 6.80 INDONESIA MARKET ANALYSIS BY PATHOGEN TYPE
81. 6.81 INDONESIA MARKET ANALYSIS BY CROP TYPE
82. 6.82 INDONESIA MARKET ANALYSIS BY DIAGNOSTIC METHOD
83. 6.83 INDONESIA MARKET ANALYSIS BY SAMPLE TYPE
84. 6.84 INDONESIA MARKET ANALYSIS BY PURPOSE OF DIAGNOSTICS
85. 6.85 REST OF APAC MARKET ANALYSIS BY PATHOGEN TYPE
86. 6.86 REST OF APAC MARKET ANALYSIS BY CROP TYPE
87. 6.87 REST OF APAC MARKET ANALYSIS BY DIAGNOSTIC METHOD
88. 6.88 REST OF APAC MARKET ANALYSIS BY SAMPLE TYPE
89. 6.89 REST OF APAC MARKET ANALYSIS BY PURPOSE OF DIAGNOSTICS
90. 6.90 SOUTH AMERICA MARKET ANALYSIS
91. 6.91 BRAZIL MARKET ANALYSIS BY PATHOGEN TYPE
92. 6.92 BRAZIL MARKET ANALYSIS BY CROP TYPE
93. 6.93 BRAZIL MARKET ANALYSIS BY DIAGNOSTIC METHOD
94. 6.94 BRAZIL MARKET ANALYSIS BY SAMPLE TYPE
95. 6.95 BRAZIL MARKET ANALYSIS BY PURPOSE OF DIAGNOSTICS
96. 6.96 MEXICO MARKET ANALYSIS BY PATHOGEN TYPE
97. 6.97 MEXICO MARKET ANALYSIS BY CROP TYPE
98. 6.98 MEXICO MARKET ANALYSIS BY DIAGNOSTIC METHOD
99. 6.99 MEXICO MARKET ANALYSIS BY SAMPLE TYPE
100. 6.100 MEXICO MARKET ANALYSIS BY PURPOSE OF DIAGNOSTICS
101. 6.101 ARGENTINA MARKET ANALYSIS BY PATHOGEN TYPE
102. 6.102 ARGENTINA MARKET ANALYSIS BY CROP TYPE
103. 6.103 ARGENTINA MARKET ANALYSIS BY DIAGNOSTIC METHOD
104. 6.104 ARGENTINA MARKET ANALYSIS BY SAMPLE TYPE
105. 6.105 ARGENTINA MARKET ANALYSIS BY PURPOSE OF DIAGNOSTICS
106. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATHOGEN TYPE
107. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY CROP TYPE
108. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSTIC METHOD
109. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY SAMPLE TYPE
110. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY PURPOSE OF DIAGNOSTICS
111. 6.111 MEA MARKET ANALYSIS
112. 6.112 GCC COUNTRIES MARKET ANALYSIS BY PATHOGEN TYPE
113. 6.113 GCC COUNTRIES MARKET ANALYSIS BY CROP TYPE
114. 6.114 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSTIC METHOD
115. 6.115 GCC COUNTRIES MARKET ANALYSIS BY SAMPLE TYPE
116. 6.116 GCC COUNTRIES MARKET ANALYSIS BY PURPOSE OF DIAGNOSTICS
117. 6.117 SOUTH AFRICA MARKET ANALYSIS BY PATHOGEN TYPE
118. 6.118 SOUTH AFRICA MARKET ANALYSIS BY CROP TYPE
119. 6.119 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSTIC METHOD
120. 6.120 SOUTH AFRICA MARKET ANALYSIS BY SAMPLE TYPE
121. 6.121 SOUTH AFRICA MARKET ANALYSIS BY PURPOSE OF DIAGNOSTICS
122. 6.122 REST OF MEA MARKET ANALYSIS BY PATHOGEN TYPE
123. 6.123 REST OF MEA MARKET ANALYSIS BY CROP TYPE
124. 6.124 REST OF MEA MARKET ANALYSIS BY DIAGNOSTIC METHOD
125. 6.125 REST OF MEA MARKET ANALYSIS BY SAMPLE TYPE
126. 6.126 REST OF MEA MARKET ANALYSIS BY PURPOSE OF DIAGNOSTICS
127. 6.127 KEY BUYING CRITERIA OF HEALTHCARE
128. 6.128 RESEARCH PROCESS OF MRFR
129. 6.129 DRO ANALYSIS OF HEALTHCARE
130. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
131. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
132. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
133. 6.133 HEALTHCARE, BY PATHOGEN TYPE, 2024 (% SHARE)
134. 6.134 HEALTHCARE, BY PATHOGEN TYPE, 2024 TO 2035 (USD Billion)
135. 6.135 HEALTHCARE, BY CROP TYPE, 2024 (% SHARE)
136. 6.136 HEALTHCARE, BY CROP TYPE, 2024 TO 2035 (USD Billion)
137. 6.137 HEALTHCARE, BY DIAGNOSTIC METHOD, 2024 (% SHARE)
138. 6.138 HEALTHCARE, BY DIAGNOSTIC METHOD, 2024 TO 2035 (USD Billion)
139. 6.139 HEALTHCARE, BY SAMPLE TYPE, 2024 (% SHARE)
140. 6.140 HEALTHCARE, BY SAMPLE TYPE, 2024 TO 2035 (USD Billion)
141. 6.141 HEALTHCARE, BY PURPOSE OF DIAGNOSTICS, 2024 (% SHARE)
142. 6.142 HEALTHCARE, BY PURPOSE OF DIAGNOSTICS, 2024 TO 2035 (USD Billion)
143. 6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY CROP TYPE, 2025-2035 (USD Billion)
  3. 7.2.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.2.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.2.5 BY PURPOSE OF DIAGNOSTICS, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY CROP TYPE, 2025-2035 (USD Billion)
  3. 7.3.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.3.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.3.5 BY PURPOSE OF DIAGNOSTICS, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY CROP TYPE, 2025-2035 (USD Billion)
  3. 7.4.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.4.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.4.5 BY PURPOSE OF DIAGNOSTICS, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY CROP TYPE, 2025-2035 (USD Billion)
  3. 7.5.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.5.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.5.5 BY PURPOSE OF DIAGNOSTICS, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY CROP TYPE, 2025-2035 (USD Billion)
  3. 7.6.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.6.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.6.5 BY PURPOSE OF DIAGNOSTICS, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY CROP TYPE, 2025-2035 (USD Billion)
  3. 7.7.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.7.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.7.5 BY PURPOSE OF DIAGNOSTICS, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY CROP TYPE, 2025-2035 (USD Billion)
  3. 7.8.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.8.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.8.5 BY PURPOSE OF DIAGNOSTICS, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY CROP TYPE, 2025-2035 (USD Billion)
  3. 7.9.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.9.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.9.5 BY PURPOSE OF DIAGNOSTICS, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY CROP TYPE, 2025-2035 (USD Billion)
  3. 7.10.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.10.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.10.5 BY PURPOSE OF DIAGNOSTICS, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY CROP TYPE, 2025-2035 (USD Billion)
  3. 7.11.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.11.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.11.5 BY PURPOSE OF DIAGNOSTICS, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY CROP TYPE, 2025-2035 (USD Billion)
  3. 7.12.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.12.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.12.5 BY PURPOSE OF DIAGNOSTICS, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY CROP TYPE, 2025-2035 (USD Billion)
  3. 7.13.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.13.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.13.5 BY PURPOSE OF DIAGNOSTICS, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY CROP TYPE, 2025-2035 (USD Billion)
  3. 7.14.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.14.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.14.5 BY PURPOSE OF DIAGNOSTICS, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY CROP TYPE, 2025-2035 (USD Billion)
  3. 7.15.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.15.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.15.5 BY PURPOSE OF DIAGNOSTICS, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY CROP TYPE, 2025-2035 (USD Billion)
  3. 7.16.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.16.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.16.5 BY PURPOSE OF DIAGNOSTICS, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY CROP TYPE, 2025-2035 (USD Billion)
  3. 7.17.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.17.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.17.5 BY PURPOSE OF DIAGNOSTICS, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY CROP TYPE, 2025-2035 (USD Billion)
  3. 7.18.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.18.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.18.5 BY PURPOSE OF DIAGNOSTICS, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY CROP TYPE, 2025-2035 (USD Billion)
  3. 7.19.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.19.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.19.5 BY PURPOSE OF DIAGNOSTICS, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY CROP TYPE, 2025-2035 (USD Billion)
  3. 7.20.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.20.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.20.5 BY PURPOSE OF DIAGNOSTICS, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY CROP TYPE, 2025-2035 (USD Billion)
  3. 7.21.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.21.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.21.5 BY PURPOSE OF DIAGNOSTICS, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY CROP TYPE, 2025-2035 (USD Billion)
  3. 7.22.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.22.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.22.5 BY PURPOSE OF DIAGNOSTICS, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY CROP TYPE, 2025-2035 (USD Billion)
  3. 7.23.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.23.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.23.5 BY PURPOSE OF DIAGNOSTICS, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY CROP TYPE, 2025-2035 (USD Billion)
  3. 7.24.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.24.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.24.5 BY PURPOSE OF DIAGNOSTICS, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY CROP TYPE, 2025-2035 (USD Billion)
  3. 7.25.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.25.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.25.5 BY PURPOSE OF DIAGNOSTICS, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY CROP TYPE, 2025-2035 (USD Billion)
  3. 7.26.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.26.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.26.5 BY PURPOSE OF DIAGNOSTICS, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY CROP TYPE, 2025-2035 (USD Billion)
  3. 7.27.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.27.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.27.5 BY PURPOSE OF DIAGNOSTICS, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY CROP TYPE, 2025-2035 (USD Billion)
  3. 7.28.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.28.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.28.5 BY PURPOSE OF DIAGNOSTICS, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY CROP TYPE, 2025-2035 (USD Billion)
  3. 7.29.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.29.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.29.5 BY PURPOSE OF DIAGNOSTICS, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY CROP TYPE, 2025-2035 (USD Billion)
  3. 7.30.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.30.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.30.5 BY PURPOSE OF DIAGNOSTICS, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Pathogen Type (USD Billion, 2025-2035)

Fungi
Bacteria
Viruses
Phytoplasmas
Nematodes

Healthcare By Crop Type (USD Billion, 2025-2035)

Cereals and Grains
Fruits and Vegetables
Oilseeds and Pulses
Fiber Crops
Specialty Crops

Healthcare By Diagnostic Method (USD Billion, 2025-2035)

Traditional Microscopy
Molecular Diagnostics
Biochemical Assays
Immunological Assays
Remote Sensing

Healthcare By Sample Type (USD Billion, 2025-2035)

Plant Tissue
Soil
Water
Air

Healthcare By Purpose of Diagnostics (USD Billion, 2025-2035)

Early Detection and Diagnosis
Disease Monitoring
Risk Assessment
Research and Development

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓